Bright Minds Biosciences (DRUG) Income towards Parent Company (2023 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Income towards Parent Company came in at $35513.3 in Q4 2024, up 102.87% YoY from $17505.4 in Q1 2024, and down 78.87% on a QoQ basis from $168091.4 in Q2 2024.
Powered by 
Analysis
Bright Minds Biosciences (DRUG) Income towards Parent Company (2023 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 2 years of Income towards Parent Company data on file, last reported at $35513.3 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Bright Minds Biosciences | 459.66 Mn | 237.12 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.75 Mn |
| Mar 31, 2026 | -9.59 Mn |
| Dec 31, 2025 | -6.01 Mn |
| Sep 30, 2025 | -9.80 Mn |
| Jun 30, 2025 | 4.13 Mn |
| Mar 31, 2025 | 2.35 Mn |
| Dec 31, 2024 | 32,422.24 |
| Sep 30, 2024 | -2.08 Mn |
| Jun 30, 2024 | 157,133.80 |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | -1.24 Mn |
| Sep 30, 2023 | -5.50 Mn |
| Jun 30, 2023 | -1.09 Mn |